| 07. 28. 2011.| 14:11 |
|
Atlantic Grupa doubled sales revenue
|
|
|
(Zoran Stankovic)
In the first half of 2011, Atlantic Grupa posted 104.8% yoy higher sales of HRK 2,197.1 million. Earnings before interest and taxes (EBIT) excluding one-off items doubled in comparison to the same period last year and amounted to HRK 127.7 million. Earnings before interest, taxes and amortization (EBITDA) excluding one-off items advanced 156.5% yoy to HRK 229.5 million, while normalized net profit before minority interests amounted to HRK 14.5 million.
The majority of sales growth came on the back
of Droga Kolinska’s consolidation, with additional contribution from the Sports
and Functional Food Division that posted the strongest organic sales growth of 19.5%,
followed by the Pharma Division with 12.5% sales growth.
During the first half of the year, the integration
of Droga Kolinska in Atlantic Grupa’s business model was successfully finalized
with a joint distribution infrastructure established on all regional markets,
merged logistics processes and developed centralized purchasing system as well as
central marketing.
- Following successful execution of key
integration activities with special emphasis on distribution and logistics on the
regional markets, in 1H11 Atlantic Grupa delivered two times higher sales and normalized
operating profitability as compared to the same period last year.The company delivered
growth on nearly all important markets, especially Serbia with organic growth of
over 9%, as well as Germany and Great Britain with double-digit growth rates. Moving
ahead, the focus is on improving and optimizing internal processes, developing
techniques for operative and financial risk management as well as active brand management
with the primary goal of achieving synergy potentials and meeting existing
financial obligations - highlighted Zoran Stankovic, Vice-president for finance
at Atlantic Grupa. In Atlantic Grupa’s total sales, the Croatian market accounted for 28.6%, followed by Serbia with 24.9%, Slovenia with 11.9% and Western Europe with 9%. Own brands, following the consolidation of Droga Kolinska’s brands, accounted for 71.6%, principal brands made up 17%, Farmacia 5.9%, while private label sales accounted for 5.5% of sales.
|
Related documents |
|

|
|